PeptiDream Inc. (TYO:4587)
Japan · Delayed Price · Currency is JPY 1,113.50
+5.00 (0.45%)
Aug 27, 2026, 10:54 AM JST
PeptiDream Financials Overview
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 19,204 | 18,521 | 46,676 | 28,712 | 26,852 | 9,366 |
Revenue Growth | 0.62% | -60.32% | 62.57% | 6.93% | 186.70% | -19.79% |
Gross Profit Gross Profit Growth | 8,324 | 7,522 | 34,503 | 17,218 | 18,113 | 7,008 |
Operating Income Operating Income Growth | -4,868 | -4,958 | 21,022 | 6,811 | 8,842 | 4,418 |
Net Income Net Income Growth | -3,626 | -3,749 | 15,014 | 3,035 | 7,554 | 3,606 |
Earnings Per Share EPS Growth | -28.10 | -28.99 | 115.68 | 23.38 | 58.14 | 27.78 |
EPS Growth | - | - | 394.78% | -59.79% | 109.29% | -18.91% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Radioactive Pharmaceutical Business Radioactive Pharmaceutical Business Growth | 16,879 | 16,104 | 16,096 | 11,474 | - |
Unallocated Adjustments Unallocated Adjustments Growth | -1,151 | -740.69 | -86.96 | -27.18 | - |
Drug Discovery and Development Business Drug Discovery and Development Business Growth | 2,793 | 31,313 | 12,703 | 15,406 | 9,366 |
Total Total Growth | 18,521 | 46,677 | 28,712 | 26,852 | 9,366 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 23,602 | 28,682 | 48,117 | 19,507 | 5,247 | 11,747 |
Total Debt Total Debt Growth | 15,688 | 17,706 | 20,351 | 22,798 | 21,675 | - |
Net Cash (Debt) Net Cash Growth | 7,914 | 10,976 | 27,766 | -3,291 | -16,428 | 11,747 |
Net Cash Growth | -47.21% | -60.47% | - | - | - | 64.30% |
Net Cash Per Share Net Cash Per Share Growth | 61.33 | 84.88 | 213.93 | -25.35 | -126.43 | 90.48 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -4,144 | -13,276 | 23,844 | 12,420 | -82 | 6,655 |
Capital Expenditures CapEx Growth | -1,248 | -1,643 | -2,077 | -1,212 | -3,721 | -1,186 |
Free Cash Flow Free Cash Flow Growth | -5,392 | -14,919 | 21,767 | 11,208 | -3,803 | 5,469 |
Free Cash Flow Growth | - | - | 94.21% | - | - | 372.74% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 43.34% | 40.61% | 73.92% | 59.97% | 67.45% | 74.82% |
Operating Margin | -25.35% | -26.77% | 45.04% | 23.72% | 32.93% | 47.17% |
Pretax Margin | -26.60% | -28.68% | 44.75% | 15.16% | 24.78% | 51.50% |
Profit Margin | -18.88% | -20.24% | 32.17% | 10.57% | 28.13% | 38.51% |
FCF Margin | -28.08% | -80.55% | 46.63% | 39.04% | -14.16% | 58.39% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 27, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 22.83 | 63.48 | 35.70 | 91.62 |
Forward PE | 13.82 | 14.52 | 28.76 | 22.60 | 37.93 | - |
P/FCF Ratio | - | - | 15.75 | 17.19 | - | 60.42 |
PS Ratio | 7.42 | 11.56 | 7.34 | 6.71 | 10.04 | 35.28 |